^
    2d
    Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (clinicaltrials.gov)
    P2, N=60, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Active, not recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    hydroxyurea • flonoltinib
    2d
    A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • thalidomide
    2d
    Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial (clinicaltrials.gov)
    P2/3, N=750, Not yet recruiting, The First Affiliated Hospital of University of Science and Technology of China
    New P2/3 trial
    2d
    Primary myelofibrosis with Factor V Leiden diagnosed following portal vein thrombosis (PubMed, Rinsho Ketsueki)
    Treatment with ruxolitinib resulted in a marked improvement in splenomegaly and symptoms related to portal hypertension...This case represents a rare instance of PMF with FVL mutation encountered in Japan. In cases of atypical-site thrombosis, particularly among Caucasian patients, comprehensive evaluation including MPN driver mutations and other thrombophilic factors is essential to avoid underdiagnosis.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    2d
    A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (clinicaltrials.gov)
    P3, N=105, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • flonoltinib
    3d
    Ocular manifestations of STAT3 gain-of-function syndrome: A case of papillitis, retinitis, and retinal vasculitis. (PubMed, Am J Ophthalmol Case Rep)
    The patient was treated with subcutaneous immunoglobulin and ruxolitinib, and clinical exam remained stable at 2-year follow up. STAT3-GOF syndrome may present with bilateral optic disc edema, retinitis, and retinal vascular leakage in the setting of recurrent infections and polyendocrinopathy. This case illustrates the role of monogenic mutations in non-neoplastic autoimmune retinopathy and highlights the importance of multidisciplinary management including genetic consultation for accurate diagnosis and targeted immunomodulatory treatment.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Jakafi (ruxolitinib)
    4d
    A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P2 trial
    |
    flonoltinib
    7d
    Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New trial
    7d
    A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases (clinicaltrials.gov)
    P3, N=220, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    8d
    Glycolytic-inflammatory crosstalk mediated by Glyco-PMF-Rux hub genes drives PMF progression and ruxolitinib resistance. (PubMed, Genes Genomics)
    STAT1, EGR1, FOXO1, and SMAD7 are associated with glycolytic-inflammatory crosstalk underlying PMF progression and ruxolitinib resistance, with experimental validation supporting STAT1 and EGR1 as potential diagnostic and therapeutic targets.
    Journal
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1) • SMAD7 (SMAD Family Member 7) • EGR1 (Early Growth Response 1)
    |
    Jakafi (ruxolitinib)
    8d
    An Uncommon Link: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in the Setting of Myeloproliferative Neoplasms. (PubMed, Cureus)
    Treatment with intermittent phlebotomy and ruxolitinib led to hematologic improvement and complete normalization of serum sodium levels without the need for continued SIADH-specific therapy...Clinicians should consider MPNs in the differential diagnosis of unexplained SIADH. Further research is warranted to elucidate the underlying pathophysiological link.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    8d
    Inhibition of UDP-glucuronosyltransferases by Fedratinib, Implying a High Risk of Drug-drug Interactions. (PubMed, Chem Biol Interact)
    Fedratinib is the second drug approved by the FDA for adult patients with myelofibrosis (MF) following ruxolitinib; however, the mechanism of its dose-limiting toxicity, particularly hepatotoxicity, remains poorly unclear. The results of risk assessment indicated that clinically relevant doses of fedratinib could significantly increase the area under curve (AUC) of drugs mainly metabolized by UGT1A1 and UGT1A3, suggesting a potential risk of clinically significant drug-drug interactions (DDIs). The current research provides useful information for the possible hepatotoxicity mechanism and clinical safe medication of fedratinib.
    Journal
    |
    UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT1A3 (UDP Glucuronosyltransferase Family 1 Member A3)
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib)